The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
Vivos Therapeutics, Inc. ( NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Kirk Huntsman - Chariman & CEO Brad Amman - CFO Scott Henry - Alliance Global Partners Lucas Ward ...
Against the backdrop of high medical costs and an imbalance of access to care, is there reason to be optimistic about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback